pI: 5.9454 |
Length (AA): 845 |
MW (Da): 94133 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 845 | 1n0u (A) | 4 | 842 | 62.00 | 0 | 1 | 1.8 | -1.27 |
4 | 845 | 1n0u (A) | 4 | 842 | 62.00 | 0 | 1 | 1.74305 | -0.67 |
729 | 806 | 2ywe (A) | 405 | 482 | 21.00 | 0.052 | 0.33 | 0.398808 | -0.95 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_126923)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G12915 | ribosomal protein S5/Elongation factor G/III/V family protein |
Arabidopsis thaliana | AT1G56070 | elongation factor EF-2-like protein LOS1 |
Babesia bovis | BBOV_I003090 | elongation factor 2, EF-2 |
Brugia malayi | Bm1_28480 | translation elongation factor aEF-2 |
Candida albicans | CaO19.13210 | Translation elongation factor EF-2 |
Candida albicans | CaO19.5788 | Translation elongation factor EF-2 |
Caenorhabditis elegans | CELE_F25H5.4 | Protein EEF-2, isoform B |
Cryptosporidium hominis | Chro.80341 | elongation factor 2 (EF-2) |
Cryptosporidium parvum | cgd8_2930 | Eft2p GTpase; translation elongation factor 2 (EF-2) |
Dictyostelium discoideum | DDB_G0287685 | elongation factor 2 |
Dictyostelium discoideum | DDB_G0288373 | elongation factor 2 |
Drosophila melanogaster | Dmel_CG2238 | Elongation factor 2 |
Echinococcus granulosus | EgrG_000865300 | elongation factor 2 |
Entamoeba histolytica | EHI_166810 | elongation factor 2 |
Entamoeba histolytica | EHI_189490 | elongation factor 2 |
Entamoeba histolytica | EHI_164510 | elongation factor 2 |
Echinococcus multilocularis | EmuJ_000865300 | elongation factor 2 |
Giardia lamblia | GL50803_17570 | Elongation factor 2 |
Homo sapiens | ENSG00000108883 | elongation factor Tu GTP binding domain containing 2 |
Homo sapiens | ENSG00000167658 | eukaryotic translation elongation factor 2 |
Leishmania braziliensis | LbrM.35.0270 | elongation factor 2 |
Leishmania donovani | LdBPK_360210.1 | elongation factor 2 |
Leishmania donovani | LdBPK_360190.1 | elongation factor 2 |
Leishmania infantum | LinJ.36.0200 | elongation factor 2 |
Leishmania infantum | LinJ.36.0210 | elongation factor 2 |
Leishmania infantum | LinJ.36.0190 | elongation factor 2 |
Leishmania major | LmjF.36.0180 | elongation factor 2 |
Leishmania major | LmjF.36.0190 | elongation factor 2 |
Leishmania mexicana | LmxM.36.0180 | elongation factor 2 |
Loa Loa (eye worm) | LOAG_05446 | translation elongation factor aEF-2 |
Mus musculus | ENSMUSG00000020929 | elongation factor Tu GTP binding domain containing 2 |
Mus musculus | ENSMUSG00000034994 | eukaryotic translation elongation factor 2 |
Neospora caninum | NCLIV_020220 | elongation factor 2, putative |
Oryza sativa | 4324669 | Os01g0723000 |
Oryza sativa | 4329493 | Os02g0519900 |
Oryza sativa | 4326544 | Os01g0742200 |
Oryza sativa | 4334959 | Os04g0118400 |
Plasmodium berghei | PBANKA_1314800 | elongation factor 2, putative |
Plasmodium falciparum | PF3D7_1451100 | elongation factor 2 |
Plasmodium knowlesi | PKNH_1231000 | elongation factor 2, putative |
Plasmodium vivax | PVX_117925 | elongation factor 2, putative |
Plasmodium yoelii | PY05356 | elongation factor 2 |
Saccharomyces cerevisiae | YOR133W | elongation factor 2 |
Saccharomyces cerevisiae | YDR385W | elongation factor 2 |
Schistosoma japonicum | Sjp_0012720 | ko:K03234 elongation factor EF-2, putative |
Schistosoma mansoni | Smp_143150 | eukaryotic translation elongation factor |
Schmidtea mediterranea | mk4.000542.01 | |
Schmidtea mediterranea | mk4.003189.00 | |
Schmidtea mediterranea | mk4.002871.03 | |
Schmidtea mediterranea | mk4.008935.01 | Putative eukaryotic translation elongation factor |
Schmidtea mediterranea | mk4.004544.07 | Putative eukaryotic translation elongation factor |
Schmidtea mediterranea | mk4.017031.02 | Putative eukaryotic translation elongation factor |
Trypanosoma brucei gambiense | Tbg972.10.5590 | elongation factor 2, putative |
Trypanosoma brucei | Tb927.10.4560 | elongation factor 2 |
Trypanosoma brucei | Tb927.10.4570 | elongation factor 2 |
Trypanosoma congolense | TcIL3000_10_3760 | elongation factor 2, putative |
Trypanosoma cruzi | TcCLB.510963.90 | elongation factor 2, putative |
Trypanosoma cruzi | TcCLB.508625.10 | elongation factor 2, putative |
Trypanosoma cruzi | TcCLB.508899.151 | elongation factor 2, putative |
Trypanosoma cruzi | TcCLB.508169.20 | elongation factor 2, putative |
Toxoplasma gondii | TGME49_205470 | translation elongation factor 2 family protein, putative |
Theileria parva | TP01_0529 | elongation factor 2, putative |
Trichomonas vaginalis | TVAG_016880 | translation factor, putative |
Trichomonas vaginalis | TVAG_276410 | translation elongation factor, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.4560 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.4560 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.4560 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.10.4560 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_F25H5.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_F25H5.4 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_F25H5.4 | Caenorhabditis elegans | slow growth | wormbase |
CELE_F25H5.4 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_1314800 | Plasmodium berghei | Essential | plasmo |
TGME49_205470 | Toxoplasma gondii | Probably essential | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.